AstraZeneca (LON:AZN) Downgraded by Citigroup to Buy

Citigroup lowered shares of AstraZeneca (LON:AZN) to a buy rating in a research report released on Friday morning, MarketBeat reports.

Several other equities research analysts also recently issued reports on the company. Jefferies Financial Group reissued a “buy” rating and issued a £180 price objective on shares of AstraZeneca in a research note on Friday, June 26th. Deutsche Bank Aktiengesellschaft restated a “sell” rating and set a £115 price target on shares of AstraZeneca in a report on Friday, June 26th. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of £153.33.

AstraZeneca Trading Down 3.9%

LON AZN opened at £128.34 on Friday. The stock has a market cap of £199.04 billion, a price-to-earnings ratio of 19.33, a PEG ratio of 0.86 and a beta of 0.23. The firm’s 50 day moving average price is £137.14 and its two-hundred day moving average price is £141.44. The company has a debt-to-equity ratio of 71.66, a quick ratio of 0.59 and a current ratio of 0.91. AstraZeneca has a twelve month low of £101.78 and a twelve month high of £157.32.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.